Safety Study of Deep Brain Stimulation to Manage Thalamic Pain Syndrome (DBS)
2017年5月1日 更新者:Andre Machado
Deep Brain Stimulation for Thalamic Pain Syndrome
The purpose of this study is to determine the safety and efficacy of Deep Brian Stimulation (DBS) of the ventral capsular/ventral striatal as a treatment for patients with Thalamic Pain Syndrome (TPS).
The central hypothesis to be tested in this investigation is that VC/VS stimulation will modulate the affective component of TPS and, consequently, improve pain related disability.
調査の概要
詳細な説明
This is a pilot clinical study of the therapeutic benefits of ventral capsular/ventral striatal deep brain stimulation (DBS) as a treatment for 10 patients with medically refractory thalamic pain syndrome.
Patients to be enrolled under this protocol will have experienced severe pain for more than six months and will be considered medically refractory.
Study subjects may have undergone and failed other surgical procedures or interventional procedures.
Study subjects will have chronic, medically refractory pain of disabling severity, refractory to treatment attempts with conventional medications.
Patients that are enrolled in the study will have bilateral DBS surgery, with implantation of one Medtronic 3391 DBS lead on either side of the brain.
These leads will then be connected at first to a single Medtronic PC pulse generator to be implanted in the infraclavicular region on one side.
Once the PC pulse generator is depleted, and the patient has completed the blinded phase of the study, the PC pulse generator will be replaced for an RC pulse generator.
The RC pulse generator has a battery life of 9 years and is a good option for the open label phase and for continued stimulation after the study is completed.
However, the RC is not ideal for the blinded phase because patients may be able to tell if they are receiving active or sham stimulation.
For this reason, patients enrolled in this study will receive, initially, the implant with the PC generator.
Patients will have at least 6 months of stable chronic pain associated with TPS.
研究の種類
介入
入学 (実際)
10
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
21年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Clinical diagnosis of thalamic pain syndrome
- with allodynia or dysesthesia
- with pinprick anesthesia or hypoesthesia on the affected hemibody (anesthesia dolorosa).
- Six months or more of medically refractory severe pain (see below).
- Pain disability reported by the pain index >30 points at the time of enrollment.
- Average daily pain for the past 30 days reported as >5 on a 0-10 scale
- Failure to respond adequately to at least one antidepressant, one anti-seizure medication and one oral narcotic.
- MRI done within one year of the first visit showing a lesion that involves the posterior thalamic region or a lesion in the dorsal or ventral vicinity of the thalamus (i.e. semi oval white matter or brain stem). The lesion will be contralateral to the hemibody affected by chronic pain or will involve cortical-subcortical areas in topography consistent with sensory thalamocortical connections. This will include patients with infarcts in the territory of the middle cerebral artery. A more recent MRI may be required if the patient's condition changed within the previous year.
- Capable of understanding and providing informed consent
- Age ≥ 21 years
- Women of childbearing age must be on regular use of an accepted contraceptive method(s).
- Previous surgical procedures: Patients with severe and refractory thalamic pain syndrome may have undergone other interventional or surgical procedures, as an attempt to alleviate the thalamic pain syndrome. Surgical procedure may include blocks, spinal cord stimulation, thalamic DBS, posterior limb of the internal capsule DBS or periaqueductal gray / periventricular gray DBS, cortical stimulation, peripheral ablative procedures or cerebral ablative procedures. In this study, patients with previously implanted cortical stimulation systems, or spinal and peripheral nervous system stimulation systems may be included. However, patients with previous motor cortex stimulation must have had the cortical stimulation system before being considered a candidate for this protocol. Removal of the cortical stimulation system will not be covered under this protocol. Patients with spinal or peripheral neuromodulation system may be included in the research provided that the implanted systems are compatible with the all research protocols (including fMRI) to be performed during the research. Patients with pervious DBS implants will not be considered candidates.
Exclusion Criteria:
- Not capable of understanding or providing informed consent.
- Aphasia severe enough to limit the consent process or communication between the investigators and the patient. Patients with mild or recovering aphasia may be considered candidates at the discretion of the PI.
- Coagulopathy. Patients will be excluded unless assessed and cleared by hematology
- Inability to stop Coumadin or platelet anti-aggregation therapy for surgery and after surgery. Patients taking these medications will need to discuss the need/risk of continuing these medications with their physicians and the PI or study personnel may contact the treating physician(s) as well to discuss the risks of anticoagulation / antiaggregation therapy discontinuation.
- Uncontrolled hypertension.
- Malignancy with < 5 years life expectancy.
- Major medical co-morbidities: end stage renal failure, heart failure, severe congestive heart disease, severe respiratory problems, liver failure or other significant medical co morbidities.
- Major neurological disorder other than the one that led to the TPS.
- MRI (done within one year of the first visit) with abnormalities other than those associated with the neurological disorder causing TPS.
- Age < 21 years.
- Pregnancy or lack of regular use of contraceptives. Patients who become pregnant after enrollment may be excluded from the study. Patients who become pregnant prior to the surgical implantation of the DBS systems will be excluded from the study.
- Previous ablative intracranial surgery for the management of the TPS.
- Previously implanted with deep brain stimulation system.
- Concurrent enrolment in any other trial / study for TPS.
- Implantable hardware not compatible with MRI or with the study.
- Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from VC/VS DBS.
- Untreated / uncontrolled (severe at the time of enrolment) depression or other psychiatric disorder.
- Bipolar disorder, current PTSD, severe personality disorder, active psychosis, Severe OCD.
- Psychological co-morbidities that indicates higher risk to the patient and / or higher risk of failure.
- Suicide attempt </= 12 months
- Communication of a plan for suicide, prior to implant, should the study treatment fail
- Imminent suicide risk
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Treatment group
Active stimulation and programmed to the settings found to be optimal during the titration process.
|
Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six.
In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group.
In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
|
|
偽コンパレータ:Control group
IPG is set to ON but the voltage is set to 0V.
|
Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six.
In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group.
In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With 50% Improvement in Pain Related Disability (as Assessed by the Pain Disability Index)
時間枠:Blinded stimulation phase (3 Months)
|
Pain Disability Index (PDI) directly measures disability related to the main components of daily life function and has been validated for thalamic pain syndrome.
Range is 0 (no disability) to 10 (worst disability).
The components are Family/Home Responsibilities, Recreation, Social Activity, Sexual Behavior, Life-support Activity, Occupation, & Self-care.
This is an average score of the 3 month period for each Active and Sham phase.
|
Blinded stimulation phase (3 Months)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants Who Had 50% Improvement in PDI
時間枠:24 months post randomization follow up
|
A 50% improvement in pain related disability (as assessed by the pain disability index) at the end of the open label phase compared to the pre-implantation baseline.
The PDI ranges from 0-10 with 0 equaling no disability and 10 equaling worst disability.
|
24 months post randomization follow up
|
|
Number of Participants Who Would Undergo the Procedure Again.
時間枠:End of Open Label Phase (24 months)
|
A positive answer from patients receiving active stimulation at the end of the open label phase of the study to the question: 'would you undergo this procedure again if you were to get the same benefits you experienced?'
|
End of Open Label Phase (24 months)
|
|
Number of Patient Who Had >50% Reduction in VAS.
時間枠:Baseline and 24 months
|
Patients report reduction in the VAS (Visual Analogue Scale Ranging from 0-10, 0 meaning no pain and 10 meaning worst pain imaginable) at the end of the open label phase (24 months post randomization f/u) compared to the pre-implantation baseline.
|
Baseline and 24 months
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
捜査官
- 主任研究者:Andre G Machado, MD、The Cleveland Clinic
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
一般刊行物
- Gopalakrishnan R, Burgess RC, Lempka SF, Gale JT, Floden DP, Machado AG. Pain anticipatory phenomena in patients with central poststroke pain: a magnetoencephalography study. J Neurophysiol. 2016 Sep 1;116(3):1387-95. doi: 10.1152/jn.00215.2016. Epub 2016 Jun 29.
- Gopalakrishnan R, Burgess RC, Plow EB, Floden DP, Machado AG. Early event related fields during visually evoked pain anticipation. Clin Neurophysiol. 2016 Mar;127(3):1855-63. doi: 10.1016/j.clinph.2015.11.019. Epub 2015 Dec 5.
- Plow EB, Malone DA Jr, Machado A. Deep brain stimulation of the ventral striatum/anterior limb of the internal capsule in thalamic pain syndrome: study protocol for a pilot randomized controlled trial. Trials. 2013 Jul 31;14:241. doi: 10.1186/1745-6215-14-241.
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2010年5月1日
一次修了 (実際)
2014年8月1日
研究の完了 (実際)
2016年3月1日
試験登録日
最初に提出
2010年2月19日
QC基準を満たした最初の提出物
2010年2月19日
最初の投稿 (見積もり)
2010年2月22日
学習記録の更新
投稿された最後の更新 (実際)
2017年6月9日
QC基準を満たした最後の更新が送信されました
2017年5月1日
最終確認日
2017年5月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。